[1] Manuel O, Avery R K. Update on cytomegalovirus in transplant recipients: new agents, prophylaxis, and cell-mediated immunity[J]. Curr Opin Infect Dis,2021,34(4):307-313.
[2] Rashidi-Alavijeh J, Crämer J C, Sauter H L, et al. Primary sclerosing cholangitis as an independent risk factor for cytomegalovirus infection after liver transplant[J]. Transpl Infect Dis,2021,23(3):e13553.
[3] Molina-Ortega A, Martín-Gandul C, Mena-Romo J, et al. Impact of pretransplant CMV-specific T-cell immune response in the control of CMV infection after solid organ transplantation: a prospective cohort study[J]. Clin Microbiol Infect,2019,25(6):753-758.
[4] Imlay H, Wagener M M, Vutien P, et al. Increasing proportion of high-risk cytomegalovirus donor-positive/recipient-negative serostatus in solid organ transplant recipients[J]. Transplantation,2022,12:738837.
[5] Limaye A P, Rahnemai-Azar A A, Nazarian S M, et al. Donor CMV reactivation as a novel risk factor for CMV replication in seropositive liver transplant recipients[J]. Transplant Direct,2021,7(1):e637.
[6] Bruminhent J, Thongprayoon C, Dierkhising R A, et al. Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?[J]. Liver Transpl,2015,21(4):539-546.
[7] Singh N, Winston D J, Razonable R R, et al. Risk factors for cytomegalovirus viremia following liver transplantation with a seropositive donor and seronegative recipient receiving antiviral therapy[J]. J Infect Dis,2021,223(6):1073-1077.
[8] Kang R, Han S, Kim J M, et al. Postoperative hyperglycemia may negatively impact cytomegalovirus infection in seropositive liver transplant recipients: a retrospective cohort study[J]. Transpl Int,2020,33(1):68-75.
[9] Møller D L, Sørensen S S, Rezahosseini O, et al. Prediction of herpes virus infections after solid organ transplantation: a prospective study of immune function[J]. Front Immunol,2023,14:1183703.
[10] Furuichi M, Fujiwara T, Fukuda A, et al. Fulminant hepatic failure as a risk factor for cytomegalovirus infection in children receiving preemptive therapy after liver transplantation[J]. Transplantation,2016,100(11):2404-2409.
[11] Yim S H, Choi M C, Kim D G, et al. Risk factors for cytomegalovirus infection and its impact on survival after living donor liver transplantation in south korea: a nested case-control study[J]. Pathogens. 2023;12(4):521.
[12] 赵宏, 范骏, 胡建华, 等. HBV感染对肝移植术后巨细胞病毒感染的影响[J]. 中华微生物学和免疫学杂志,2010,30(2):150-153.
[13] Busch C J, Siegler B H, Werle H, et al.Risk factors for early viral infections after liver transplantation[J]. Langenbecks Arch Surg,2018,403(4):509-519.
[14] 寇建涛, 朱继巧, 樊华, 等. 肝移植术后巨细胞病毒感染的危险因素分析[J]. 中华外科杂志,2015,53(4):270-273.
[15] Nierenberg N E, Poutsiaka D D, Chow J K, et al. Pretransplant lymphopenia is a novel prognostic factor in cytomegalovirus and noncytomegalovirus invasive infections after liver transplantation[J]. Liver Transpl,2014,20(12):1497-1507.
[16] Gardiner B J, Nierenberg N E, Chow J K, et al. Absolute lymphocyte count: a predictor of recurrent cytomegalovirus disease in solid organ transplant recipients[J]. Clin Infect Dis,2018,67(9):1395-1402.
[17] Aldridge R W, Mattes F M, Rolando N, et al. Effects of donor/recipient human leukocyte antigen mismatch on human cytomegalovirus replication following liver transplantation[J]. Transpl Infect Dis,2015,17(1):25-32.
[18] Kijpittayarit S, Eid A J, Brown R A, et al. Relationship between Toll-like receptor 2 polymorphism and cytomegalovirus disease after liver transplantation[J]. Clin Infect Dis,2007,44(10):1315-1320.
[19] Fernández-Ruiz M, Giménez E, Lora D, et al. Impact of MBL2 gene polymorphisms on the risk of infection in solid organ transplant recipients: a systematic review and meta-analysis[J]. Am J Transplant,2019,19(4):1072-1085.
[20] Mizuno S, Nakatani K, Muraki Y, et al. Combination assays for evaluation of immune function and CYP3A5 genotype to identify the risk of infectious complications and mortality in living donor liver transplant patients[J]. Ann Transplant,2013,18:349-357.
[21] Katsolis J G, Bosch W, Heckman M G, et al. Evaluation of risk factors for cytomegalovirus infection and disease occurring within 1 year of liver transplantation in high-risk patients[J]. Transpl Infect Dis,2013,15(2):171-180.
[22] 何晓顺, 郭志勇, 鞠卫强, 等. 无缺血肝移植技术的创立——附三例报告[J]. 中华器官移植杂志,2017,38(10):577-583.
[23] Hung H C, Hsu P J, Lee J C, et al. Plasma cytomegalovirus DNA load predicts outcomes in liver transplant recipients[J]. Immun Inflamm Dis,2021,9(1):134-143.
[24] McBride J M, Sheinson D, Jiang J, et al. Correlation of cytomegalovirus (CMV) disease severity and mortality with CMV viral burden in CMV-seropositive donor and CMV-seronegative solid organ transplant recipients[J]. Open Forum Infect Dis,2019,6(2):ofz003.
[25] Doss K M, Heldman M R, Limaye A P. Updates in cytomegalovirus prevention and treatment in solid organ transplantation[J]. Infect Dis Clin North Am,2023,20:S0891-5520(23)00083-1.
[26] Zeidan J H, Kamionek M, Noell B C, et al. Late onset CMV disease presenting as a colonic stricture in a liver transplant recipient[J]. Transpl Infect Dis,2020,22(2):e13259.
[27] Vutien P, Perkins J, Biggins S W, et al. Association of donor and recipient cytomegalovirus serostatus on graft and patient survival in liver transplant recipients[J]. Liver Transpl,2021,27(9):1302-1311.
[28] Härmä M, Höckerstedt K, Lyytikäinen O, et al. HHV-6 and HHV-7 antigenemia related to CMV infection after liver transplantation[J]. J Med Virol,2006,78(6):800-805.
[29] DesJardin J A, Cho E, Supran S, et al. Association of human herpesvirus 6 reactivation with severe cytomegalovirus-associated disease in orthotopic liver transplant recipients[J]. Clin Infect Dis,2001,33(8):1358-1362.
[30] Hoppe L, Marroni C A, Bressane R, et al. Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients[J]. Transplant Proc,2006,38(6):1922-1923.
[31] Choi D, Thaker S, West-Thielke P, et al. Evaluating the conversion to extended-release tacrolimus from immediate-release tacrolimus in liver transplant recipients[J]. Eur J Gastroenterol Hepatol,2021,33(8):1124-1128.
[32] Lin C C, Chuang F R, Lee C H, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation[J]. Liver Transpl,2005,11(10):1258-1264.
[33] Penninga L, Wettergren A, Wilson C H, et al. Antibody induction versus corticosteroid induction for liver transplant recipients[J]. Cochrane Database Syst Rev,2014,5:CD010252.
[34] Yadav D K, Adhikari V P, Yadav R K, et al. Antiviral prophylaxis or preemptive therapy for cytomegalovirus after liver transplantation?A systematic review and meta-analysis[J]. Front Immunol,2022,13:953210.
[35] Zamora D, Dasgupta S, Stevens-Ayers T, et al. Cytomegalovirus immunity in high-risk liver transplant recipients following preemptive antiviral therapy vs. prophylaxis[J]. JCI Insight,2024,23:e180115.
[36] Kumar L, Dasgupta S, Murray-Krezan C, et al. Association of cytomegalovirus (CMV) DNAemia with long-term mortality in a randomized trial of preemptive therapy and antiviral prophylaxis for prevention of CMV disease in high-risk donor seropositive, recipient seronegative liver transplant recipients[J]. Clin Infect Dis,2024,78(3):719-722. |
